This prospective randomized study aims to evaluate the effect of adjunctive hemostatic agents (FloSeal® and Surgicel®) on perioperative outcomes in patients undergoing partial nephrectomy for localized renal tumors. A total of 150 patients were randomized into three groups: standard parenchymal suturing (Group A), suturing with FloSeal® (Group B), and suturing with Surgicel® (Group C). The study primarily investigates whether hemostatic agents reduce postoperative hemorrhage, urinary leakage, and positive surgical margin rates. Secondary outcomes include renal function change, operative and ischemia times, estimated blood loss, and hospital stay. All surgeries were performed by a single experienced surgeon at Ankara University Urology Department between January 2023 and December 2024.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged 18 years or older.
* Diagnosed with localized renal mass (clinical stage T1a-T1b) suitable for partial nephrectomy.
* Adequate preoperative renal function to undergo surgery.
* Signed informed consent obtained prior to study enrollment.
* Undergoing open, laparoscopic, or robotic partial nephrectomy performed by the same experienced surgeon.
Exclusion Criteria:
* Patients with solitary kidney or bilateral renal tumors.
* History of previous renal surgery on the same kidney.
* Evidence of metastatic disease or locally advanced (≥T2) renal tumors.
* Coagulopathy, bleeding disorders, or ongoing anticoagulant therapy that cannot be discontinued.
* Active urinary tract infection or systemic infection.
* Known allergy or hypersensitivity to gelatin or oxidized cellulose components.
* Patients who decline participation or withdraw consent.
* Incomplete perioperative data or loss to follow-up.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of clinically significant postoperative hemorrhage requiring blood transfusion
Timeframe: From postoperative Day 0 through postoperative Day 30
2
Incidence of postoperative urinary leakage or fistula
Timeframe: From postoperative Day 0 through postoperative Day 30
3
Rate of positive surgical margins
Timeframe: At pathological assessment (Day of surgery)